CLVS2: A Potential Drug Target and Biomarker (G134829)

Target Name: CLVS2

NCBI ID: G134829

CLVS2

CLVS2: A Potential Drug Target and Biomarker

CLVS2, or clathrin vesicle-associated Sec14 protein 2, is a protein that is expressed in various cell types, including neurons and glial cells in the central nervous system. It is a member of the CLVS2 family, which is known for its role in the formation and maintenance of tight junctions, which are specialized barriers that regulate the movement of ions and molecules into and out of cells.

Recent studies have suggested that CLVS2 may have potential as a drug target and biomarker for various neurological and psychiatric disorders. In addition to its role in tight junction formation, CLVS2 has also been shown to be involved in a number of other cellular processes that are relevant to disease, including the regulation of neurotransmitter release, cell signaling, and inflammation.

One potential mechanism by which CLVS2 may be involved in the development and progression of neurodegenerative disorders is its role in the regulation of the trafficking of neurotransmitter-producing neurons. CLVS2 has been shown to interact with the neurotransmitter synaptophysin, a protein that is involved in the delivery of neurotransmitters to synapses. By modulating the trafficking of synaptophysin, CLVS2 may be able to affect the number and type of neurotransmitters that are available in the brain, potentially contributing to the development of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

Another potential mechanism by which CLVS2 may be involved in the development and progression of psychiatric disorders is its role in the regulation of inflammation. CLVS2 has been shown to interact with the chemokine receptor CXCR1, a protein that is involved in the regulation of immune responses and inflammation. By modulating the activity of CXCR1, CLVS2 may be able to affect the production and activity of immune cells, potentially contributing to the development of psychiatric disorders such as anxiety and depression.

In addition to its potential role in neurotransmitter regulation and inflammation, CLVS2 has also been shown to be involved in a number of other cellular processes that are relevant to disease. For example, CLVS2 has been shown to play a role in the regulation of cell signaling, including the regulation of protein kinase C (PKC) signaling. Additionally, CLVS2 has been shown to interact with the transcription factor p300, a protein that is involved in the regulation of gene expression and cell signaling.

Given the potential involvement of CLVS2 in a number of cellular processes that are relevant to disease, as well as its expression in a variety of cell types, CLVS2 may be an attractive target for drug development. In addition to its potential therapeutic applications, CLVS2 may also be a valuable biomarker for the diagnosis and progression of various psychiatric and neurological disorders.

In conclusion, CLVS2 is a protein that has important roles in a variety of cellular processes that are relevant to disease. Its potential as a drug target and biomarker make it an attractive target for further study and development. Further research is needed to fully understand the mechanisms by which CLVS2 is involved in disease and to develop effective treatments.

Protein Name: Clavesin 2

Functions: Required for normal morphology of late endosomes and/or lysosomes in neurons (By similarity). Binds phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2)

The "CLVS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLVS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets